KetamineOne Capital says its common shares have been successfully uplisted to the OTCQB
The company’s common shares will begin trading on the OTCQB under the symbol KONEF as of the opening of the market today, January 12, 2022
Sector
Health
1090 stories · page 38 of 55
EU drug watchdog doubts need for fourth COVID-19 vaccine dose
"While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy," said EMA official Marco Cavaleri
Braxia Scientific closes C$3M private placement to fund expansion of clinics and investments
The company issued 30 million common shares, or common share equivalents, together with warrants to buy up to an aggregate of 30 million common shares at a purchase price of C$0.10 each
Hygrovest is new name for MMJ Group Holdings
The company believes the new name more accurately reflects its future operations in line with a broadening of its investment mandate.
Ketamine One says its subsidiary KGK Science becomes first founding sponsor of Psychedelic Science 2023 event
The event, scheduled for June 19-25, 2023 in Denver, Colorado with an estimated 10,000 attendees, will be the world’s largest gathering of the psychedelic ecosystem
ANGLE technology used in lung cancer drug resistance study
Researchers in Greece used the company's Parsortix liquid biopsy to harvest tumour cells for analysis
Stifel GMP encouraged by US$5M investment into Mindset Pharma, which provides "further validation for psychedelic sector"
As reported by Mindset, the tie-up consists of a US$5 million upfront cash payment and operational support to develop two 2nd generation psychedelic families in Mindset's pipeline through phase 1a and phase 1b trials
Energy stocks lead the way as ASX rises while WOW withdraws bid for API
Woolworths had proposed to acquire API at a cash offer price of $1.75 a share, however, said it could not validate the financial returns it requires in line with the group’s capital allocation framework.
Braxia Scientific enters an agreement with institutional investors for a private placement to raise gross proceeds of approximately C$3M
The company said the net proceeds of the private placement will be used for the expansion of clinics, certain strategic investments and general working capital purposes
Binovi Technologies appoints Jatinder Dhaliwal as its CEO and a director
"With Mr. Dhaliwal's appointment, Binovi will enhance its access to capital markets and health care industry networks, which will be valuable assets towards the execution on Binovi's strategy and conversion of business prospects,“ said Terr
MGC Pharmaceuticals says India approves food supplement to alleviate COVID-19 symptoms
Managing director Roby Zomer says MGC is “pleased to have the opportunity to alleviate the symptoms of COVID-19 in one of the largest populated countries in the world”
KetamineOne Capital Limited appoints two new members to its Medical Advisory Board
Dr. Corey Hilmas, the chief regulatory officer of its subsidiary KGK Science, will be the board's' interim chair and will serve with new member, Brigadier General (Ret.) Dr. Loree K. Sutton
Mindset Pharma recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds
As the company enters 2022, it is progressing with investigational new drug-enabling studies for its lead candidate MSP-1014
Proactive weekly health highlights: Sensyne, RedX Pharma, Open Orphan and more
Here are the health sector highlights for the past week.
Pathway Health starts trading on the Frankfurt Stock Exchange
"Listing on the Frankfurt Stock Exchange will provide Pathway Health with direct access to the European capital markets and an opportunity for the company to increase trading liquidity and facilitate investment by expanding our shareholder
Ketamine One reports strong 1Q results following transition to medical clinics consolidator
“We are pleased with Ketamine One’s financial results for the first quarter of the 2022 fiscal year, as revenue during the three-month period ending October 31st exceeded that for all of the 2021 fiscal year,” interim CEO Adam Deffett said.
KetamineOne Capital appoints Joe Ramelli as its chief financial officer
"Mr Ramelli comes to our organization as a highly recommended professional and we are looking forward to learning from his expertise,” said Adam Deffett, Interim CEO of Ketamine One
NA Proactive news snapshot: MAS Gold, Binovi Technologies, Emmaus Life Sciences, Kootenay Silver, Progressive Planet Solutions UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Braxia Scientific hits milestone as landmark psilocybin clinical trial begins with participants receiving first doses
"This remedy offers a potential and innovative treatment avenue for adults with treatment-resistant depression,” said Braxia Scientific CEO Dr Roger McIntyre
Mydecine Innovations is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics
At the heart, Mydecine’s core philosophy is that Psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best-accredited research organizations demonstrating its clinical effecti